# Fischer Medical Ventures (NSE: FISCHER) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FISCHER · Pivot · prices to 21 Oct 2026

Fischer Medical Ventures (NSE: FISCHER) closed at ₹25.01 on 21 Oct 2026, down 6.84% on the day. With a market capitalisation of ₹1,720 Cr, it ranks 1207th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.

At its last close the stock traded at 58.4× trailing earnings, against a return on equity of 0.4% in FY25. Over the past year the share price has fallen 73.2%. Its 52-week range is ₹24.66 (21 Oct 2026) to ₹121.70 (29 Oct 2025); the last close is 79.4% below the high. Promoters held 62.15% of the company as of 30 Jun 2026; 7.38% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹25.01 |
| Market cap | ₹1,720 Cr |
| P/E (trailing) | 58.4 |
| ROE | 0.4% (FY25) |
| ROCE | 0.9% (FY25) |
| Debt to equity | 0.18 |
| 52-week high | ₹121.70 (29 Oct 2025) |
| 52-week low | ₹24.66 (21 Oct 2026) |
| 1-year return | −73.2% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹111 Cr | ₹2 Cr |
| FY24 | ₹21 Cr | ₹2 Cr |
| FY23 | ₹0 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 62.15%
- Foreign institutions: 5.48%
- Domestic institutions: 1.35%
- Non-institutions: 31.02%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Hester Biosciences](https://app.pivotnow.in/stock/HESTERBIO) | ₹2,230.60 | ₹1,898 Cr | 33 | — |
| [Beta Drugs](https://app.pivotnow.in/stock/BETA) | ₹1,682.60 | ₹1,865 Cr | 41.2 | — |
| [Windlas Biotech](https://app.pivotnow.in/stock/WINDLAS) | ₹896.70 | ₹1,850 Cr | 28.8 | — |
| [Titan Biotech](https://app.pivotnow.in/stock/TITANBIO) | — | ₹1,793 Cr | — | — |
| [NGL Fine-Chem](https://app.pivotnow.in/stock/NGLFINE) | ₹2,680.00 | ₹1,656 Cr | 34.4 | — |
| [Krsnaa Diagnostics](https://app.pivotnow.in/stock/KRSNAA) | ₹507.85 | ₹1,647 Cr | 16.4 | — |

## Questions and answers

### What is the share price of Fischer Medical Ventures today?

Fischer Medical Ventures (NSE: FISCHER) last closed at ₹25.01 on 21 Oct 2026. Its 52-week high is ₹121.70 and its 52-week low is ₹24.66.

### What is the market cap of Fischer Medical Ventures?

Fischer Medical Ventures' market capitalisation is ₹1,720 Cr (₹1,720 Cr) at the 21 Oct 2026 close, ranking 1207th among the NSE companies Pivot tracks.

### What is the P/E ratio of Fischer Medical Ventures?

Fischer Medical Ventures trades at a trailing P/E of 58.4. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 33.

### What is the ROE and ROCE of Fischer Medical Ventures?

Return on equity was 0.4% in FY25 and return on capital employed was 0.9% in FY25 (consolidated figures).

### Is Fischer Medical Ventures a debt-free company?

No. Fischer Medical Ventures' debt-to-equity ratio was 0.18 in FY25, with total debt of ₹0 Cr.

### How has Fischer Medical Ventures stock performed over the last year?

Fischer Medical Ventures' share price has fallen 73.2% over the past year, −34.1% over three months and −21.3% over one month, to the 21 Oct 2026 close.

### What is the shareholding pattern of Fischer Medical Ventures?

As of 30 Jun 2026: promoters 62.15%, foreign institutions 5.48%, domestic institutions 1.35%, non-institutions 31.02%. 7.38% of promoter shares were pledged.

### Who are Fischer Medical Ventures' competitors?

The listed Pharma & Healthcare companies closest to Fischer Medical Ventures by market cap are Hester Biosciences, Beta Drugs, Windlas Biotech, Titan Biotech, NGL Fine-Chem and Krsnaa Diagnostics.

### Is Fischer Medical Ventures a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Fischer Medical Ventures' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FISCHER against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.